Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


A novel host-proteome signature for distinguishing between acute bacterial and viral infections.

Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, Kriger O, Bamberger E, Fonar Y, Yacobov R, Wolchinsky R, Denkberg G, Dotan Y, Hochberg A, Reiter Y, Grupper M, Srugo I, Feigin P, Gorfine M, Chistyakov I, Dagan R, Klein A, Potasman I, Eden E.

PLoS One. 2015 Mar 18;10(3):e0120012. doi: 10.1371/journal.pone.0120012. eCollection 2015.


Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.

Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, Stauss H, Reiter Y.

J Immunol. 2014 Dec 1;193(11):5733-43. doi: 10.4049/jimmunol.1301769. Epub 2014 Oct 31.


Therapeutic antibodies: Discovery and development using the ProteOn XPR36 biosensor interaction array system.

Bronner V, Denkberg G, Peled M, Elbaz Y, Zahavi E, Kasoto H, Reiter Y, Notcovich A, Bravman T.

Anal Biochem. 2010 Nov 15;406(2):147-56. doi: 10.1016/j.ab.2010.07.005. Epub 2010 Aug 3.


Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.

Michaeli Y, Denkberg G, Sinik K, Lantzy L, Chih-Sheng C, Beauverd C, Ziv T, Romero P, Reiter Y.

J Immunol. 2009 May 15;182(10):6328-41. doi: 10.4049/jimmunol.0801898.


Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

Klechevsky E, Gallegos M, Denkberg G, Palucka K, Banchereau J, Cohen C, Reiter Y.

Cancer Res. 2008 Aug 1;68(15):6360-7. doi: 10.1158/0008-5472.CAN-08-0928.


Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.

Denkberg G, Stronge VS, Zahavi E, Pittoni P, Oren R, Shepherd D, Salio M, McCarthy C, Illarionov PA, van der Merwe A, Besra GS, Dellabona P, Casorati G, Cerundolo V, Reiter Y.

Eur J Immunol. 2008 Mar;38(3):829-40. doi: 10.1002/eji.200737518.


The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation.

McCarthy C, Shepherd D, Fleire S, Stronge VS, Koch M, Illarionov PA, Bossi G, Salio M, Denkberg G, Reddington F, Tarlton A, Reddy BG, Schmidt RR, Reiter Y, Griffiths GM, van der Merwe PA, Besra GS, Jones EY, Batista FD, Cerundolo V.

J Exp Med. 2007 May 14;204(5):1131-44. Epub 2007 May 7.


Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.

Denkberg G, Reiter Y.

Autoimmun Rev. 2006 Apr;5(4):252-7. Epub 2005 Aug 8. Review.


The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts.

Tzukerman M, Rosenberg T, Reiter I, Ben-Eliezer S, Denkberg G, Coleman R, Reiter Y, Skorecki K.

Cancer Res. 2006 Apr 1;66(7):3792-801.


T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.

Noy R, Eppel M, Haus-Cohen M, Klechevsky E, Mekler O, Michaeli Y, Denkberg G, Reiter Y.

Expert Rev Anticancer Ther. 2005 Jun;5(3):523-36. Review.


Simultaneous monitoring of binding to and activation of tumor-specific T lymphocytes by peptide-MHC.

Cohen CJ, Denkberg G, Schiffenbauer YS, Segal D, Trubniykov E, Berke G, Reiter Y.

J Immunol Methods. 2003 Jun 1;277(1-2):39-52.


Generation of recombinant immunotoxins for specific targeting of tumor-related peptides presented by MHC molecules.

Cohen CJ, Denkberg G, Segal D, Reiter Y.

Methods Mol Biol. 2003;207:269-82. No abstract available.


Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins.

Niv R, Cohen CJ, Denkberg G, Segal D, Reiter Y.

Curr Pharm Biotechnol. 2001 Mar;2(1):19-46. Review.


Supplemental Content

Loading ...
Support Center